Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sci-B-Vac vs Engerix-B in Healthy Adults
NCT04209400Phase 3Completed
- Sponsor
- VBI Vaccines Inc.
- Start
- Apr 2014
- Primary completion
- Apr 2015
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Hepatitis B vaccine in hepatitis B (HBV) (2 arms), sponsored by VBI Vaccines Inc. Primary endpoint: Seroconversion Rate (Proportion of subjects with anti-HBs levels >= 2.1 mIU/mL) at Day 210. Started Apr 2014; status: completed.
02
Drugs
Hepatitis B vaccine
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT04209400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04209400.